Long-term follow-up and successful treatment of pulmonary alveolar proteinosis without hypercholesterolemia with statin therapy: a case report

J Int Med Res. 2021 Apr;49(4):3000605211010046. doi: 10.1177/03000605211010046.

Abstract

Pulmonary alveolar proteinosis (PAP) is a rare disorder characterized by the accumulation of excessive surfactant lipids and proteins in alveolar macrophages and alveoli. Oral statin therapy is a novel treatment for PAP with hypercholesterolemia. However, this treatment has never been described in a patient without hypercholesterolemia. Here, we present a case of successful treatment with atorvastatin for a patient with possibly unclassified PAP without hypercholesterolemia who responded poorly to whole lung lavage therapy and inhaled granulocyte-macrophage colony-stimulating factor. After 18 months of atorvastatin treatment, the patient experienced improvements in dyspnea, radiographic abnormalities and pulmonary function. The present case study supports the feasibility of statin therapy for PAP regardless of the level of cholesterol.

Keywords: Pulmonary alveolar proteinosis; cholesterol; granulocyte-macrophage colony-stimulating factor; hypercholesterolemia; statin; therapy.

Publication types

  • Case Reports

MeSH terms

  • Follow-Up Studies
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Hypercholesterolemia* / drug therapy
  • Pulmonary Alveolar Proteinosis* / diagnostic imaging
  • Pulmonary Alveolar Proteinosis* / drug therapy

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Granulocyte-Macrophage Colony-Stimulating Factor